Patents by Inventor Joan-Josep Guinovart Cirera

Joan-Josep Guinovart Cirera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders
    Publication number: 20080206356
    Abstract: Pharmaceutical compositions comprising an effective amount of a tungsten (VI) compound, preferably of a tungstate salt, and more preferably of sodium tungstate (Na2WO4), are useful for the prophylactic and/or therapeutical treatment of neurodegenerative disorders in a mammal, including a human, in particular, for the prophylactic and/or therapeutical treatment of Alzheimer's disease or schizophrenia. The effect of sodium tungstate dihydrate on the phosphorylation of tau in a model of rat insulin resistance and in a model of type-1 diabetes has been assessed. The therapeutic treatment of tauopathies that derives from this invention involves several advantages: it targets a GSK3; specificity since it reduces the abnormal hyperphosphorylation of a neural specific protein, tau, efficacy, lack of toxicity, and low price.
    Type: Application
    Filed: July 28, 2006
    Publication date: August 28, 2008
    Applicants: UNIVERSIDAD DE BARCELONA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Joan Josep Guinovart Cirera, Jesus Avila De Grado, Jorge Dominguez Reyes, Ramon Gomis De Barbara, Alberto Gomez Ramos, Delia Zafra Lopez, Helena Corominola Ocana
  • Oral compositions for the treatment of non-diabetic obese mammals, including humans
    Patent number: 7122209
    Abstract: Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in rats has been determined in a cafeteria-diet-induced obesity model. Said obese rats are good models of obese, non-diabetic mammals, including humans. The prophylactic, therapeutic and/or cosmetic treatment resulting from this invention is surprising. It provides advantages such as effectiveness, lack of toxicity and relatively low price in comparison with other treatments in prior art. Hence, the oral compositions according to the invention are useful for the treatment of obesity/overweightness in non-diabetic mammals, including humans.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: October 17, 2006
    Assignee: Quimica Farmaceutica Bayer S.A.
    Inventors: Ramon Gomis De Barbara, Marc Claret Carles, Joan-Josep Guinovart Cirera, Josefa Fernandez Alvarez
  • Oral compositions for the treatment of obese non-diabetic mammals, including humans
    Publication number: 20040131697
    Abstract: Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in rats has been determined in a cafeteria-diet-induced obesity model. Said obese rats are good models of obese, non-diabetic mammals, including humans. The prophylactic, therapeutic and/or cosmetic treatment resulting from this invention is surprising. It provides advantages such as effectiveness, lack of toxicity and relatively low price in comparison with other treatments in prior art. Hence, the oral compositions according to the invention are useful for the treatment of obesity/overweightness in non-diabetic mammals, including humans.
    Type: Application
    Filed: November 14, 2003
    Publication date: July 8, 2004
    Inventors: Ramon Gomis De Barbara, Marc Claret Carles, Joan-Josep Guinovart Cirera, Josefa Fernandez Alvarez